VolitionRx issues shares to Lind to satisfy note payment and conversion obligations
VolitionRx reported in an 8-K signed August 7, 2026 that it issued shares to Lind Global Asset Management XII LLC to meet payment and conversion terms tied to earlier convertible notes.
VolitionRx Limited filed a Form 8-K with an earliest event date of August 6, 2026, signed August 7, 2026, disclosing recent share issuances to Lind Global Asset Management XII LLC under Item 3.02, Unregistered Sales of Equity Securities.
The filing traces back to a securities purchase agreement first dated May 15, 2025 and amended and restated on January 7, 2026. Under that agreement, VolitionRx issued to Lind senior secured convertible promissory notes in the original principal amounts of $7,500,000 and $2,400,000.1
To meet obligations tied to those notes, the company issued to Lind an aggregate of 116,651 shares of common stock on July 14, 2026 to satisfy a $133,333 payment obligation, 372,023 shares on July 16, 2026 to satisfy a $416,666 payment obligation, and 290,697 shares on August 6, 2026 to satisfy a $200,000 conversion obligation.1
According to the filing, the offering and sale of the shares underlying the note relied on exemptions under Section 3(a)(9) or alternatively Section 4(a)(2) of the Securities Act of 1933, and/or Rule 506 of Regulation D, along with corresponding state securities law provisions.1 The company further stated that the share issuance went to an existing securityholder, involved no paid commissions, did not constitute a public offering, and was made without general solicitation or advertising.1
The report was signed on behalf of VolitionRx by Cameron Reynolds, Chief Executive Officer and President, dated August 7, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.